Novel genes and sex differences in COVID-19 severity

Sex differences; COVID-19Diferències de sexe; COVID-19Diferencias de sexo; COVID-19Here, we describe the results of a genome-wide study conducted in 11 939 coronavirus disease 2019 (COVID-19) positive cases with an extensive clinical information that were recruited from 34 hospitals across Spain (SCOURGE consortium). In sex-disaggregated genome-wide association studies for COVID-19 hospitalization, genome-wide significance (P < 5 × 10−8) was crossed for variants in 3p21.31 and 21q22.11 loci only among males (P = 1.3 × 10−22 and P = 8.1 × 10−12, respectively), and for variants in 9q21.32 near TLE1 only among females (P = 4.4 × 10−8). In a second phase, results were combined with an independent Spanish cohort (1598 COVID-19 cases and 1068 population controls), revealing in the overall analysis two novel risk loci in 9p13.3 and 19q13.12, with fine-mapping prioritized variants functionally associated with AQP3 (P = 2.7 × 10−8) and ARHGAP33 (P = 1.3 × 10−8), respectively. The meta-analysis of both phases with four European studies stratified by sex from the Host Genetics Initiative (HGI) confirmed the association of the 3p21.31 and 21q22.11 loci predominantly in males and replicated a recently reported variant in 11p13 (ELF5, P = 4.1 × 10−8). Six of the COVID-19 HGI discovered loci were replicated and an HGI-based genetic risk score predicted the severity strata in SCOURGE. We also found more SNP-heritability and larger heritability differences by age (<60 or ≥60 years) among males than among females. Parallel genome-wide screening of inbreeding depression in SCOURGE also showed an effect of homozygosity in COVID-19 hospitalization and severity and this effect was stronger among older males. In summary, new candidate genes for COVID-19 severity and evidence supporting genetic disparities among sexes are provided.Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B., COV20_00181 to C.A., COV20_1144 to M.A.J.S., PI20/00876 to C.F.); European Union (ERDF) ‘A way of making Europe’. Fundación Amancio Ortega, Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.)

A Simple Entropic-Driving Separation Procedure of Low-Size Silver Clusters, Through Interaction with DNA

Synthesis and purification of metal clusters without strong binding agents by wet chemical methods are very attractive for their potential applications in many research areas. However, especially challenging is the separation of uncharged clusters with only a few number of atoms, which renders the usual techniques very difficult to apply. Herein, we report the first efficient separation of Ag2 and Ag3 clusters using the different entropic driving forces when such clusters interact with DNA, into which Ag3 selectively intercalates. After sequential dialysis of the samples and denaturalizing the DNA-Ag3 complex, pure Ag2 can be found in the dialysate after extensive dialysis. Free Ag3 is recovered after DNA denaturation

Seguridad alimentaria y nutricional en México durante la pandemia por SARS-CoV-2: Revisión sistemática

Introduction: The food security and nutrition of individuals was affected due to the coronavirus (COVID-19) pandemic. Increased food insecurity limits individuals from having a full and dignified quality of life. Objective: To assess the access and availability of food security in the Mexican population affected by the COVID-19 pandemic in Mexico through a literature review. Methods: Literature review in databases such as: PubMed, Science Direct, Scielo, FAO, UN, ENSANUT, Salud Pública de México and CONACYT. The search for information was carried out from November 2021 to May 2022, considering articles published from March 2020 and in relation to the health contingency period. A search equation was used for the search and, in addition, the methodological evaluation of Munns et al., was applied. Articles in Spanish and English were included, with content referring to Mexico. Results: A total of 274 articles were identified in databases; based on the eligibility criteria, surveys and/or articles on nutrition, food security and lifestyle during the pandemic in Mexico were considered. Articles were excluded for having another study design (2), title (100), abstract (82), non-relevant information (54) and (9) for full text, because they did not meet the proposed characteristics. Finally, 10 articles were selected for the literature review. With this, the data showed that the COVID-19 pandemic caused diverse affectations in the Mexican territory, this was evidenced after an increase in food insecurity and changes in lifestyle. Conclusions: Food security and nutrition of individuals were affected in the Mexican population, due to economic issues, changes in dietary patterns, as well as job losses and loss of income.Introducción: La seguridad alimentaria y nutricional de los individuos se vio afectada, debido a la pandemia por el coronavirus (COVID-19). El incremento de la inseguridad alimentaria limita a los individuos a tener una calidad de vida plena y digna. Objetivo: Evaluar el acceso y disponibilidad de la seguridad alimentaria en la población mexicana afectada por la pandemia de COVID-19 en México mediante una revisión de literatura. Metodología: Revisión de literatura en bases de datos como: PubMed, ScienceDirect, Scielo, FAO, ONU, ENSANUT, Salud Pública de México y CONACYT. La búsqueda de información se realizó de noviembre de 2021 a mayo de 2022, se consideraron artículos publicados a partir de marzo de 2020 y en relación con el periodo de contingencia sanitaria. Para la búsqueda se empleó una ecuación de búsqueda y, además, se aplicó la evaluación metodológica de Munns y cols. Fueron incluidos artículos en idioma español e inglés, con contenido referente a México. Resultados: Se identificaron 274 artículos en bases de datos, a partir de los criterios de elegibilidad se contemplaron encuestas y/o artículos sobre nutrición, seguridad alimentaria y estilo vida durante la pandemia en México. Se excluyeron artículos por tener otro diseño de estudio (2), título (100), resumen (82), información no relevante (54) y (9) por texto completo, debido a que no cumplían con las características propuestas. Finalmente se seleccionaron 10 artículos para la revisión de literatura. Con esto, los datos mostraron que la pandemia por COVID-19 provocó diversas afectaciones en el territorio mexicano, esto se evidenció tras un incremento de la inseguridad alimentaria y cambios en el estilo de vida. Conclusiones:  La seguridad alimentaria y nutrición de los individuos se vieron afectados en la población mexicana, debido a cuestiones económicas, cambios en los patrones alimentarios, además de pérdidas de empleo y pérdidas de ingresos

Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial

Background: given our preclinical data showing synergy between dovitinib and paclitaxel in preclinical models we conducted this phase I trial aiming to define the recommended phase II-dose (RP2D) on the basis of toxicity and pharmacodynamic criteria while searching for genetic variants that could sensitize patients to the regimen under study. Patients and methods: a 3+3 escalation schedule was adopted. Seriated FGF23 and dovitinib and paclitaxel pharmacokinetic profiles were determined along a single-agent dovitinib 'priming-phase' followed by a dovitinib + paclitaxel combination phase. RECIST 1.1 criteria and NCI CTCAE V.4.0 were used. In fresh pre-treatment tumor biopsy samples, FGFR1, 2 and 3 amplifications were revealed by FISH probes; 32 missense variants were genotyped in tumors and peripheral blood mononuclear cells with Taqman genotyping assays (FGFR1-3 and RET). Constructs encoding for wild-type and variant genes associated with clinical benefit were transfected into HEK-293 cells for preclinical experiments checking constitutive activation and dovitinib sensitivity of the variants. Results: twelve patients were recruited in three dose-levels. At level 1B (200 mg dovitinib 5-days-on/2-days-off plus 60 mg/m 2-week of paclitaxel) more than 50% FGF23 upregulation was observed and no dose-limiting-toxicities (DLTs) occurred. The most frequent toxicities were asthenia, neutropenia, nausea/vomiting and transaminitis. Two patients with progressive disease prior to trial inclusion achieved prolonged disease stabilization. Both had the germline variant G2071A in the RET gene, which led to constitutive activation of the protein product and Y-905 phosphorylation, both in transfectants and in patients with the alteration. This variant was sensitive to dovitinib; in addition both patients experienced progression upon medication withdrawal. Conclusions: level 1B was the RP2D as it provided adequate pharmacodynamic exposure to dovitinib. The G2071A germline variant act as a genetic modifier that renders different tumors sensitive to dovitinib

Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET

This work was supported by the following sources: Fondo de Investigacion Sanitaria (Ministry of Health, Spain; numbers FIS PI10/0288, FIS PI13/00430, FIS PI 11/00616, CPII14/00005 and FIS PI14/00860; the first two awarded to MQF and the last three to MD), and "Fondo Europeo de Desarrollo Regional (FEDER) - Una manera de hacer Europa". MQF is a recipient of a 2010 Beca-Retorno from the AECC Scientific Foundation. Rosae Foundation and AVON Espana S.A.U. contributed to this work with unrestricted donations. Dovitinib was kindly provided by Novartis.BACKGROUND: Rationalization of antiangiogenics requires biomarkers. Vascular re-normalization is one widely accepted mechanism of action for this drug class. The interstitium of tumors with abnormal vasculature is hypoxic. We sought to track vascular normalization with (18)F-misonidazole ([18F]-FMISO, a probe that detects hypoxia) PET, in response to window-of-opportunity (WoO) treatment with the antiangiogenic dovitinib. METHODS: Two patient-derived pancreas xenografts (PDXs; Panc215 and Panc286) and the spontaneous breast cancer model MMTV-PyMT were used. Animals were treated during 1 week of WoO treatment with vehicle or dovitinib, preceded and followed by [18F]-FMISO-PET, [18F]-FDG-PET, and histologic assessment (dextran extravasation, hypoxia and microvessel staining, and necrosis, cleaved caspase-3 and Ki67 measurements). After WoO treatment, gemcitabine (pancreas)/adriamycin (breast) or vehicle was added and animals were treated until the humane endpoint. Tumor growth inhibition (TGI) and survival were the parameters studied. RESULTS: [18F]-FMISO SUV did not change after dovitinib-WoO treatment compared to vehicle-WoO (0.54 vs. 0.6) treatment in Panc215, but it decreased significantly in Panc286 (0.58 vs. 1.18; P < 0.05). In parallel, 10-KDa perivascular dextran extravasation was not reduced with dovitinib or vehicle-WoO treatment in Panc215, but it was reduced in Panc286. Whereas the addition of dovitinib to gemcitabine was indifferent in Panc215, it increased TGI in Panc286 (TGI switched from -59% to +49%). [18F]-FMISO SUV changes were accompanied by an almost 100% increase in interstitial gemcitabine delivery (665-1260 ng/mL). The results were validated in the PyMT model. CONCLUSIONS: [18F]-FMISO accurately monitored vascular re-normalization and improved interstitial chemotherapy delivery.This work was supported by the following sources: Fondo de Investigacion Sanitaria (Ministry of Health, Spain; numbers FIS PI10/0288, FIS PI13/00430, FIS PI 11/00616, CPII14/00005 and FIS PI14/00860; the first two awarded to MQF and the last three to MD), and "Fondo Europeo de Desarrollo Regional (FEDER) - Una manera de hacer Europa". MQF is a recipient of a 2010 Beca-Retorno from the AECC Scientific Foundation. Rosae Foundation and AVON Espana S.A.U. contributed to this work with unrestricted donations. Dovitinib was kindly provided by Novartis.S